Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036972 · ClinicalTrials.gov registry record · Phase 1
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00036972: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00036972 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036972, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma. PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy before and after surgery in treating patients who have recurrent malignant glioma.
Interventions
- PROCEDURE conventional surgery
- PROCEDURE adjuvant therapy
- BIOLOGICAL cintredekin besudotox
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036972
The ClinicalTrials.gov registry entry for NCT00036972 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which conventional surgery is the first listed.
NCT00036972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036972 about?
NCT00036972 is a clinical study titled "Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma". RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma. PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy before and after surgery in treating patients who have recurrent mal...
What is the current status of trial NCT00036972?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00036972?
The interventions under investigation include: conventional surgery (PROCEDURE), adjuvant therapy (PROCEDURE), cintredekin besudotox (BIOLOGICAL), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00036972?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.